Medical, research, ethics
advisory board

Dr. Chin Sze Piaw

MBBS, MRCP (UK), FNHAM (Mal)

Leads the regulatory, pre-clinical and clinical research activities at Cytopeutics

Dr Chin Sze Piaw qualified with an MBBS from Newcastle UK in 1995 and obtained his MRCP in 1998. He is currently a consultant physician and cardiologist at the CMH Specialist Hospital and Honorary Fellow of the Centre for Stem Cell Research, Faculty of Medicine & Health Sciences, Universiti Tunku Abdul Rahman.

Dr Chin has served on expert committees for clinical practice guidelines, and several research and registry steering committees for cardiovascular disease and stem cell research.  His own research interest in heart failure and stem cell therapy has led to over 60 publications in international peer-reviewed journals and presentations at international medical conferences. Among the cutting-edge research includes the demonstration of clinical anti-inflammatory and immunomodulatory actions of mesenchymal stem cells (MSC) and successful treatments of cardiomyopathy, stroke and diabetes complications and osteoarthritis.

 

Dr Chin was jointly awarded patents from the USA for his pioneering use of MSC treatment for acute stroke, vernal keratoconjunctivitis and diabetes. His other patents include use of stem cells for severe heart failure, auto-immune disease, pre-diabetes and diabetes complications, and macular oedema. Dr Chin has been a joint recipient of numerous grants for his stem cell research including the ERGS and FRGS grants from the Ministry of Higher Education, the MOSTI Technofund, The Impak Perdana award and the Toray Foundation award from Japan.

In 2018, Dr Chin and colleagues obtained another landmark approval from the regulatory authorities under the Ministry of Health, to undertake a large multicentre clinical trial of acute Graft versus Host Disease (aGVHD). In 2021, Dr Chin was one of several experts from Asia to discuss about use of MSC for COVID-19.

Dr Chin leads the regulatory, pre-clinical and clinical research activities at Cytopeutics.

Dr Chin was jointly awarded patents from the USA for his pioneering use of MSC treatment for acute stroke, vernal keratoconjunctivitis and diabetes. His other patents include use of stem cells for severe heart failure, auto-immune disease, pre-diabetes and diabetes complications, and macular oedema. Dr Chin has been a joint recipient of numerous grants for his stem cell research including the ERGS and FRGS grants from the Ministry of Higher Education, the MOSTI Technofund, The Impak Perdana award and the Toray Foundation award from Japan.

In 2018, Dr Chin and colleagues obtained another landmark approval from the regulatory authorities under the Ministry of Health, to undertake a large multicenter clinical trial of acute Graft versus Host Disease (aGVHD). In 2021, Dr Chin was one of several experts from Asia to discuss about use of MSC for COVID-19.

Dr Chin Sze Piaw leads the regulatory, pre-clinical and clinical research activities at Cytopeutics.

Prof. Dr. Chin Kin Fah

MBChB, FRCS (Glasgow), MD, FRCS (General Surgery), CCST, FCPS, AM

Advisor for clinical research activities by Cytopeutics

Prof. Dr. Chin Kin Fah graduated in medicine from the University of Aberdeen in 1993. He was awarded Intercollegiate Fellowship in General Surgery and Upper GI surgery and Certificate of Completion of Specialist Training (CCST) in United Kingdom in 2005. He completed his Senior Fellowship in Upper GI and Laparoscopic surgery in Adelaide in 2006.

Prof. Dr. Chin Kin Fah is the pioneer of the ‘SILENT MENTOR’ Program in Malaysia, a humanity program that promotes body donation for betterment and benefit of Medical Education, Training & Research. He launched the program in 2012 while he was a professor at the University of Malaya. In 2017, he formed Academy for Silent Mentor which promotes the program to whole Malaysia, collaborates with various Universities, and benefiting to more Malaysia’s medical students.

Prof. Dr. Chin Kin Fah is an advisor for clinical research activities by Cytopeutics.

Emeritus Prof. Dr. Cheong Soon Keng

MBBS (Malaya), MRCP (UK), DCP (London), FRCP (Glasg),FRCP (Edin), FRCPA (Australia), FAMM (Malaysia),FAM (Singapore), FFScRCPA (Australia) ,FASc (Malaysia)

Advisor for research and development activities and ethical conduct by Cytopeutics

Emeritus Prof. Dr. Cheong Soon Keng has over 40 years of medical experience in clinical medicine and pathology. Prof Cheong’s impressive medical experience includes the role of the Professor of Haematology in the Faculty of medicine, Universiti Kebangsaan Malaysia, and Head of the Department of Laboratory Diagnostic Services and Head of Clinical Haematology & Stem Cell Transplant Services of Hospital Universiti Kebangsaan Malaysia. Prof Cheong performed the first haemopoietic stem cell transplantation for hospital UKM in 1999. Prof Cheong pioneered a new approach in stem cell transplantation using peripheral blood stem cells rather than the bone marrow, and the non-myeloablative conditioning regimen which extended the age limit of the recipients of transplantation.

In 1994, he was one of the Founding Council Members of the National Cancer Council (MAKNA), a not-for-profit charity organization, setup up to fight cancer and help cancer patients. He initiated the collaboration between Hospital UKM and the National Cancer Council (MAKNA), establishing the MAKNA-HUKM Cancer Institute to provide cancer services to cancer patients in April 1999. After retirement from UKM, Prof Cheong continues to participate in cell-based clinical trials carried out in this centre, until today.

Prof Cheong is currently Senior Professor of Medicine of Universiti Tunku Abdul Rahman, Emeritus Professor of Haematology of Universiti Kebangsaan Malaysia, and Honorary Professor of Universiti Malaya.

Prof Cheong has been involved in research on stem cells for many decades. In early 2000, Prof Cheong became interested in Mesenchymal Stem Cells (MSCs) found in the human bone marrow, MSCs were first isolated and developed in his laboratory for clinical use for the first time in Malaysia. These MSCs are now undergoing clinical trials in collaboration with industry partners.

In the 2010s, Prof Cheong’s research group in Universit Tunku Abdul Rahman (UTAR) was the first to generate Induced Pluripotent Stem Cells (iPSC) in Malaysia. In 2008, he was elected as President of the College of Pathologists, Academy of Medicine of Malaysia (CPathAMM). He initiated the International Congress of Pathology & Laboratory Medicine which is now held biennially. In 2009, Prof Cheong was invited to be the Founding Dean of UTAR Faculty of Medicine & Health Sciences, a post he has held until now. In November 2017. Prof Cheong was appointed by the Minister of Health as an Appointed Member of the Malaysian Medical Council, which is a corporate entity under the revised Medical Act 1971 and the regulator of the medical profession.

In 2021 Emeritus Professor Dr. Cheong was appointed 2021 Senior Fellow of the Academy of Sciences Malaysia in recognition of his leadership in medical education and research, particularly in haematology and stem cell transplantation.

Prof Dr. Cheong Soon Keng is an advisor for research and development activities and ethical conduct by Cytopeutics. 

Prof. Dr. S Fadilah S Abdul Wahid

MD(UKM), DrIntMed (UKM), PhD (QLD), FRCP (EDIN), JCMTP (Japan), AM (MAL)

Advisor for clinical research development in regenerative medicine and immunotherapy for Cytopeutics

Prof Dr S Fadilah graduated with a MB,BS in 1997 and obtained the Masters of internal Medicine from UKM in 1997. She was conferred a a Doctor of Philosophy (PhD) degree from the University of Queensland, Australia in the field of cancer immunotherapy in 2004. In 2007, she received the Fellowship award of the Royal College of Physicians of Edinburgh (FRCPE) and was promoted to the position of Professor. Subsequently, she was appointed Head of the Medical Department of UKM for two terms, from 2007 to 2012.

Prof. Dr. S Fadilah established the Cell Therapy Center (PTS) in 2010 and was appointed Head of PTS until 2021. The main mission of PTS is for UKM to be the leader and leading reference center in cell medicine in the region to meet the urgent unmet needs in blood cancer treatment in the country. this. Currently, PTS is one of the Centers of Excellence in PPUKM that provides not only comprehensive blood cancer treatment but is active in research, training, and teaching activities. In addition to leading the field of blood cancer treatment and research based on hematopoietic stem cells and immune cells, PTS has also successfully pioneered the field of regenerative medicine which has enabled PTS to be known as a leading reference center in cell -based medicine in the country.

Prof Fadilah leads several research groups that bring together experts in the fields of cell therapy, hematology, oncology, radiotherapy, interventional radiology, and nuclear medicine from Japan, the USA, China and Malaysia. She has published more than 100 scientific papers in journals and presented more than 100 conference papers and was the first author for the Cochrane Database of Systematic Reviews. She has also been appointed commentator and editorial board member for international and local journals. She is also frequently invited as a lead author and co -author in the writing of blood cancer treatment guidelines and cell therapy at the national and international levels.

She was appointed as a board member for the National Transplant Board, Ministry of Health Malaysia (MOH) and a panel member for the Malaysia National Transplant Registry since 2007 until now. She also frequently receives appointments as a manager, advisor, evaluator, and committee member from various government agencies and non -governmental organizations such as MOSTI, MOH, MESTEC, DCA, and Cytopeutics Sdn. Bhd. due to her extensive expertise and experience in the field of cell therapy and blood cancer.

By the permission of Allah, she has been bestowed several awards for her contributions covering various dimensions including clinical services, research, teaching and administration. She and her team at PTS, UKM intend to continue to work hard to find the latest medical technology that is safe and effective in order to improve the cure rate and quality of life of blood cancer patients in the region.

Prof S Fadilah is an advisor for clinical research development in regenerative medicine and immunotherapy for Cytopeutics.

Dr. Qizhou Lian

M.D., Ph.D

Advisor and Authorized Person to ensure the quality of the product by Cytopeutics

Dr Qizhou Lian received his doctoral degree of Medicine (M.D., Ph.D.) from Harbin Medical University and completed his Cardiology Fellow in the First Hospital of Peking Medical University. In 2001 he accepted a NMRC Postdoctoral Fellowship from National University of Singapore, to study stem cell & developmental biology and regenerative medicine. In 2006-07 he was a visiting Research Scientist in experimental Cardiology at Utrecht Medical Centre, Netherlands, and a Research Scientist at National University Medical Institute, Singapore. Dr Lian joined the University of Hong Kong in 2008.

Dr Lian is a practicing Authorized Person (AP) for Advanced Therapy Products (ATP) registered on the Pharmacy & Poisons Board of Hong Kong. He currently serves as Scientific Officer at the HKUMed Laboratory of Cellular Therapeutics, the first cell therapy GMP manufacturing unit in the University of Hong Kong (HKU). Dr Lian also holds a joint Principle Investigator in the HKU Shenzhen Hospital, an honorary Professor in Peking University Shenzhen Hospital and Guangzhou Medical University Women and Children’s Medical Centre. He leads a dynamic interdisciplinary research group that collaborates with academic institutions, industry partners, and leading clinicians. 

Dr Lian has more than 20 years of experiences in translational research, bioprocessing development and biomanufacturing of stem cell- and gene-based therapies.  He led the Asia’s first hematopoietic stem cell gene therapy and saved patients with a genetic neurodegenerative disease, metachromatic leukoencephalopathy (MLD).

Dr Lian is also among a few Authorized Person (AP) from Asia certified by the European Union (EU) defined in Article 48 of Directive 2001/83/EC which represents the quality release of the batch of cellular and gene therapy products (CGTP) before it is released for sale or distribution. As an AP Dr Lian can certify that a process or test has been conducted in accordance with GMP and the relevant marketing authorization or clinical trial authorization, product specification file and/or technical agreement, as applicable, as agreed in writing with the AP responsible for certifying the finished product batch before release. The AP providing a confirmation takes responsibility for those activities being confirmed. The AP is responsible for ensuring that each individual batch has been manufactured and checked in compliance with laws in force in the Member State where certification takes place, in accordance with the requirements of the marketing authorization (MA) and with Good Manufacturing Practice (GMP).

Dr Qizhou Lian is an advisor and Authorized Person to ensure the quality of the product by Cytopeutics.

Dato’ Dr. Mashitah Binti Ibrahim

DIMP (Pahang), DSDK (Kedah), PhD

Advisor for Syariah Compliance of products and Ethical conduct by Cytopeutics

Dato ‘Dr. Mashitah Ibrahim is well known in the national higher education arena as she served as a lecturer at the International Islamic University of Malaysia (UIAM) for 16 years from 1988 to 2004. Kedah-born child in secondary education at Mahmud College, Alor Setar, Kedah (1977-1982) it has a distinguished background in higher education, a Bachelor of Interpretation and Hadith from Al-Azhar University of Egypt (1984-1987) and holds a Shariah Islamic Master’s Degree (1994) and Doctor of Philosophy (PhD) Shariah Islamiyyah (1997) from Darul Ulum, University of Cairo, Egypt. In fact, she also holds a Master’s degree in ‘Revealed Knowledge and Heritage’ from UIAM (1991)

She began to intervene in politics when she won the Baling Parliament in 2004 General Elections and continued to be trusted by the Government to serve as Parliamentary Secretary in the Prime Minister’s Department (2004-2008). In 2008, then Prime Minister Tun Abdullah Ahmad Badawi appointed her as Deputy Minister in the Prime Minister’s Department through her appointments as Senator.

Dato ‘Dr. Mashitah Ibrahim has been appointed to the Board of Directors of the Islamic University of Malaysia (USIM) for a two-year period from September 28, 2020 to September 27, 2022. Her appointment was made by YB Dato’ Noraini Ahmad, Minister of Higher Education is in accordance with Section 17 (1) (f) of the USIM Constitution (Private Representative).

 

Other than that, Dato’ Dr. Mashitah also serves and contributes to various other fields related to Islamic institutions, education and industry including the Executive Director Yayasan Pembangunan Pondok Malaysia (2012-present)Director Grand Commerce Network Sdn. Bhd (2014-present)Panel Perunding Majlis Perundingan Islam (MPI) Jabatan Kemajuan Islam Malaysia (JAKIM) (2015-2018); and gained the trust of the Majlis Raja-Raja as Ahli Lembaga Penasihat Penyelarasan Pelajaran dan Pendidikan Agama Islam (LEPAI) from 2006-2014.

The management is pleased and welcomes this appointment as believes in the experience of Dato’ Dr. Mashitah Ibrahim will be able to make a significant contribution to bring Cytopeutics towards greater organizational progress in the future.

Dr. Then Kong Yong

MBBS (London), FRCS (Edin), MSc (London), CCT (UK)

Advisor for good manufacturing practice (GMP) and leads the cell manufacturing and storage for Cytopeutics

Dr Then Kong Yong obtained his Bachelor of Medicine, Bachelor of Surgery (MBBS) from St. George’s Hospital, University of London. He also has a Masters degree in biochemistry and molecular biology from King’s College, University of London.  In addition, he has done a fellowship in stem cell and tissue engineering at Keele University. Dr. Then became a Fellow of the Royal College of Surgeon, Edinburgh in 1999. He is registered with the General Medical Council (U.K.) and Malaysian medical Council specialist registry.

In 1997 Dr.Then was tasked with setting up a cell banking  facility which was later upgraded to become a fully GMP-compliant facility and the largest stem cell processing clean room in South East Asia, with state-of-the-art equipment, and implemented an automated SCADA security system as well as other safe-proof programs which remains a gold standard to this day. Being a Chief Technical Officer for CryoCord Sdn Bhd, has also been involved in ISO 13485, 15189 and AABB cord blood banking standards. He is a visiting senior lecturer at Malaysia National University Hospital, a consultant at International Specialist Eye Centre as well as being an honorary fellow in stem cells research at University Tunku Abdul Rahman. He currently has over 70 publications.

Dr. Then is an advisor for good manufacturing practice (GMP) and leads the cell manufacturing and storage for Cytopeutics.